期刊
NATURE REVIEWS CANCER
卷 11, 期 11, 页码 805-812出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc3153
关键词
-
类别
资金
- Howard Hughes Medical Institute
- Ludwig Center for Cancer Immunotherapy
- Prostate Cancer Foundation
- M. D. Anderson Cancer Center
- Doris Duke Charitable Foundation
- Cancer Research Institute
- Melanoma Research Alliance Young Investigator Award
- American Cancer Society
- US Department of Defense
The US Food and Drug Administration (FDA) recently approved two novel immunotherapy agents, sipuleucel-T and ipilimumab, which showed a survival benefit for patients with metastatic prostate cancer and melanoma, respectively. The mechanisms by which these agents provide clinical benefit are not completely understood. However, knowledge of these mechanisms will be crucial for probing human immune responses and tumour biology in order to understand what distinguishes responders from non-responders. The following next steps are necessary: first, the development of immune-monitoring strategies for the identification of relevant biomarkers; second, the establishment of guidelines for the assessment of clinical end points; and third, the evaluation of combination therapy strategies to improve clinical benefit.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据